Clinical Trials on Parkinson Disease in Japan

Total 6940 results

InSightec

Recruiting

A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications

Movement Disorders | Parkinsons Disease | Neurology

United States, Japan
Kyowa Kirin Co., Ltd.

Completed

A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin

Parkinson's Disease

Japan
Kyowa Kirin Co., Ltd.

Completed

A Study of Single and Multiple Doses of KW-6356 in Healthy Subjects

Parkinson's Disease

Japan
Kyowa Kirin Co., Ltd.

Completed

Long-Term Safety Study of KW-6500 in Patients With Parkinson's Disease

Parkinson's Disease

Japan
Kyowa Kirin Co., Ltd.

Completed

Long-Term Safety Study of KW-6002 (Istradefylline) in Parkinson's Disease Patients (6002-010)

Parkinson's Disease

Japan
Kyowa Kirin Co., Ltd.

Completed

A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease

Parkinson's Disease

Japan
Takeda

Completed

Rasagiline Tablets Special Drug Use-Results Survey "Survey on Long-term Safety"

Parkinson's Disease

Japan
H. Lundbeck A/S

Completed

A Trial Investigating Lu AF28996 in Adult Japanese Participants With Parkinson's Disease (PD)

Parkinson Disease

Japan
Kyowa Kirin Co., Ltd.

Completed

A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa

Parkinson's Disease

Japan
Kyowa Kirin Co., Ltd.

Completed

A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa

Parkinson's Disease

Japan
Kyowa Kirin Co., Ltd.

Completed

Study of KW-6002 (Istradefylline) for the Treatment of Parkinson's Disease in Patients Taking Levodopa (6002-009)

Parkinson's Disease

Japan
InSightec

Completed

A Clinical Trial for the Safety and Effect of MRGuided FUS Subthalamotomy for Medication Refractory Parkinson's Disease

Parkinson Disease

Japan
Kyowa Kirin Co., Ltd.

Completed

Extended Long-Term Safety Study of KW-6500 (6500-005)

Parkinson's Disease

Japan
Kissei Pharmaceutical Co., Ltd.

Completed

A Clinical Study of KDT-3594 in Japanese Patients With Early Parkinson's Disease

Parkinson Disease

Japan
Kissei Pharmaceutical Co., Ltd.

Completed

A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.

Parkinson Disease

Japan
Kyowa Kirin Co., Ltd.

Completed

A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations

Parkinson's Disease

Japan
Kyowa Kirin Co., Ltd.

Completed

Placebo-Controlled Double-Blind Crossover Comparative Study of KW-6500 (6500-004)

Parkinson's Disease

Japan
Jichi Medical University
Takara Bio Inc.; Gene Therapy Research Institution,Co.,Ltd.

Terminated

AADC Gene Therapy for Parkinson's Disease

Parkinson Disease

Japan
SNLD, Ltd.

Active, not recruiting

Phase II Clinical Study of TR-012001 in Japanese Patients With Parkinson's Disease

Parkinson Disease

Japan
Kyowa Kirin Co., Ltd.

Completed

A Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin

Parkinson's Disease

Japan
AbbVie

Recruiting

An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's Disease

Parkinson's Disease (PD)

Japan
Kyowa Kirin Co., Ltd.

Completed

Observational Study for Non-motor Symptoms and Treatment in Parkinson's Disease Patients (J-FIRST)

Parkinson Disease

Japan
Kyowa Kirin Co., Ltd.

Completed

A Through QT/QTc Study of KW-6356

Parkinson's Disease

Japan
Osaka University
Japan Agency for Medical Research and Development

Unknown

A Study of Neurofeedback for the Treatment of Parkinson's Disease

Parkinson Disease

Japan
Kissei Pharmaceutical Co., Ltd.

Completed

Clinical Study of KDT-3594 in Healthy Adult Males and Patients With Parkinson's Disease

Parkinson Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients

Early Parkinson's Disease

Japan
Sumitomo Pharma Co., Ltd.

Completed

A Pharmacodynamics and Safety Study of DSP-9632P in Patients With Levodopa-Induced Dyskinesia in Parkinson's Disease

Parkinson's Disease | Levodopa-induced Dyskinesia

Japan
InSightec

Unknown

Safety and Initial Effectiveness of Transcranial MR Guided Focused Ultrasound for the Treatment of Parkinson's Disease (TDPD)

Parkinson Disease

China, Japan
Kyowa Kirin Co., Ltd.

Completed

Phase 2 Clinical Study of KW-6500 in Parkinson's Disease Patients With Motor Response Complication on Levodopa Therapy

Parkinson's Disease

Japan
AbbVie

Completed

An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications

Advanced Parkinson's Disease

Japan, Korea, Republic of, Taiwan
GlaxoSmithKline

Completed

Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease (PD)

Parkinson Disease

Japan
Eisai Co., Ltd.

Active, not recruiting

A Study of Equfina® on the Incidences of Adverse Drug Reactions in Participants With Parkinson's Disease (Including Participants With Hepatic Impairment)

Parkinson Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Dose-ranging Study for SPM 962 in Parkinson's Disease Patients

Parkinson's Disease

Japan
Novo Nordisk A/S

Enrolling by invitation

An Observational Study of Patients With Moderate Parkinson's Disease (TRANSCEND 1)

Parkinson Disease

United States, Japan, Sweden, United Kingdom
GlaxoSmithKline

Terminated

A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients.

Parkinson Disease

Japan
GlaxoSmithKline

Completed

REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study

Parkinson's Disease | Parkinson Disease

Japan
Kyowa Kirin Co., Ltd.

Completed

A Study of KW-6356 in Subjects With Early Parkinson's Disease

Parkinson's Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients

Parkinson's Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Dose-finding Study for SPM 962 in Advanced Parkinson's Disease Patients

Parkinson's Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-Term Extension Trial From Late Phase II of SPM 962 in Advanced Parkinson's Disease Patients

Parkinson's Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients

Parkinson's Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients

Parkinson's Disease

Japan
GlaxoSmithKline

Completed

Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease

Parkinson Disease

Japan
Biogen

Terminated

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease

Parkinson's Disease

Japan
University Medical Center Groningen
University of Sao Paulo; Dokkyo Medical University; Somogy Megyei Kaposi Mór... and other collaborators

Unknown

Beam Walking Across the Lifespan for Falls Prediction (BEAM)

Stroke | Parkinson Disease | Cognitive Impairment | Dementia | Aging | Postural; Defect | Diagnoses Disease

Netherlands, Brazil, Germany, Hungary, Japan
Boehringer Ingelheim

Completed

A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period

Parkinson Disease

Japan
Boehringer Ingelheim

Completed

Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients

Early Parkinson Disease (Early PD)

United States, Argentina, Austria, Czech Republic, Finland, Germany, Hungary, India, Japan, Malaysia, Russian Federation, Slovakia, Taiwan, Ukraine
AbbVie

Active, not recruiting

Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease

Parkinson's Disease (PD)

United States, Australia, Belgium, Canada, Denmark, Germany, Italy, Japan, Netherlands, Russian Federation, Spain, Sweden, United Kingdom
Takeda

Completed

A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants

Parkinson's Disease

Japan
AbbVie

Completed

A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)

Parkinson's Disease (PD)

United States, Australia, Belgium, Canada, Denmark, Germany, Italy, Japan, Netherlands, Russian Federation, Spain, Sweden, United Kingdom

3

Subscribe